224 related articles for article (PubMed ID: 27183845)
1. Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: A prospective cohort study.
Podlipnik S; Carrera C; Sánchez M; Arguis P; Olondo ML; Vilana R; Rull R; Vidal-Sicart S; Vilalta A; Conill C; Malvehy J; Puig S
J Am Acad Dermatol; 2016 Sep; 75(3):516-524. PubMed ID: 27183845
[TBL] [Abstract][Full Text] [Related]
2. Surveillance strategies in the follow-up of melanoma patients: too much or not enough?
Kurtz J; Beasley GM; Agnese D; Kendra K; Olencki TE; Terando A; Howard JH
J Surg Res; 2017 Jun; 214():32-37. PubMed ID: 28624057
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of imaging strategy for an intensive follow-up of patients with American Joint Committee on Cancer stage IIB, IIC and III malignant melanoma.
Podlipnik S; Moreno-Ramírez D; Carrera C; Barreiro A; Manubens E; Ferrandiz-Pulido L; Sánchez M; Vidal-Sicart S; Malvehy J; Puig S
Br J Dermatol; 2019 May; 180(5):1190-1197. PubMed ID: 29876940
[TBL] [Abstract][Full Text] [Related]
4. Routine restaging PET/CT and detection of initial recurrence in sentinel lymph node positive stage III melanoma.
Baker JJ; Meyers MO; Frank J; Amos KD; Stitzenberg KB; Ollila DW
Am J Surg; 2014 Apr; 207(4):549-54. PubMed ID: 24674829
[TBL] [Abstract][Full Text] [Related]
5. Findings of computed tomography in stage IIB and IIC melanoma: a six-year retrospective study in the South-East of Scotland.
Orfaniotis G; Mennie JC; Fairbairn N; Butterworth M
J Plast Reconstr Aesthet Surg; 2012 Sep; 65(9):1216-9. PubMed ID: 22525255
[TBL] [Abstract][Full Text] [Related]
6. Commentary: Improved patient outcomes remain elusive after intensive imaging surveillance for high-risk melanoma.
Swetter SM
J Am Acad Dermatol; 2016 Sep; 75(3):525-527. PubMed ID: 27317056
[No Abstract] [Full Text] [Related]
7. Prospective evaluation of follow-up in melanoma patients in Germany - results of a multicentre and longitudinal study.
Livingstone E; Krajewski C; Eigentler TK; Windemuth-Kieselbach C; Benson S; Elsenbruch S; Hauschild A; Rompel R; Meiss F; Mauerer A; Kähler KC; Dippel E; Möllenhoff K; Kilian K; Mohr P; Utikal J; Schadendorf D
Eur J Cancer; 2015 Mar; 51(5):653-67. PubMed ID: 25638778
[TBL] [Abstract][Full Text] [Related]
8. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma.
Poo-Hwu WJ; Ariyan S; Lamb L; Papac R; Zelterman D; Hu GL; Brown J; Fischer D; Bolognia J; Buzaid AC
Cancer; 1999 Dec; 86(11):2252-8. PubMed ID: 10590365
[TBL] [Abstract][Full Text] [Related]
9. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy.
Wagner JD; Schauwecker D; Davidson D; Coleman JJ; Saxman S; Hutchins G; Love C; Hayes JT
J Clin Oncol; 1999 May; 17(5):1508-15. PubMed ID: 10334538
[TBL] [Abstract][Full Text] [Related]
10. Melanoma Prognosis: Accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition.
Bajaj S; Donnelly D; Call M; Johannet P; Moran U; Polsky D; Shapiro R; Berman R; Pavlick A; Weber J; Zhong J; Osman I
J Natl Cancer Inst; 2020 Sep; 112(9):921-928. PubMed ID: 31977051
[TBL] [Abstract][Full Text] [Related]
11. Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients.
Lee AY; Droppelmann N; Panageas KS; Zhou Q; Ariyan CE; Brady MS; Chapman PB; Coit DG
Ann Surg Oncol; 2017 Apr; 24(4):939-946. PubMed ID: 27804026
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the eighth American Joint Committee on Cancer staging system for malignant melanoma of the skin.
Abdel-Rahman O
Future Oncol; 2018 Feb; 14(5):471-481. PubMed ID: 29322826
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of reduced follow-up in malignant melanoma.
Hengge UR; Wallerand A; Stutzki A; Kockel N
J Dtsch Dermatol Ges; 2007 Oct; 5(10):898-907. PubMed ID: 17910672
[TBL] [Abstract][Full Text] [Related]
14. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging.
Meyers MO; Yeh JJ; Frank J; Long P; Deal AM; Amos KD; Ollila DW
Ann Surg Oncol; 2009 Apr; 16(4):941-7. PubMed ID: 19101766
[TBL] [Abstract][Full Text] [Related]
15. Primary staging and follow-up in melanoma patients--monocenter evaluation of methods, costs and patient survival.
Hofmann U; Szedlak M; Rittgen W; Jung EG; Schadendorf D
Br J Cancer; 2002 Jul; 87(2):151-7. PubMed ID: 12107834
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy.
Garbe C; Paul A; Kohler-Späth H; Ellwanger U; Stroebel W; Schwarz M; Schlagenhauff B; Meier F; Schittek B; Blaheta HJ; Blum A; Rassner G
J Clin Oncol; 2003 Feb; 21(3):520-9. PubMed ID: 12560444
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of ultrasound B-scan compared with physical examination in follow-up of melanoma patients.
Voit C; Mayer T; Kron M; Schoengen A; Sterry W; Weber L; Proebstle TM
Cancer; 2001 Jun; 91(12):2409-16. PubMed ID: 11413532
[TBL] [Abstract][Full Text] [Related]
18. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines.
Francken AB; Shaw HM; Accortt NA; Soong SJ; Hoekstra HJ; Thompson JF
Ann Surg Oncol; 2007 Jun; 14(6):1924-33. PubMed ID: 17357855
[TBL] [Abstract][Full Text] [Related]
19. Costs of the detection of metastases and follow-up examinations in cutaneous melanoma.
Leiter U; Marghoob AA; Lasithiotakis K; Eigentler TK; Meier F; Meisner C; Garbe C
Melanoma Res; 2009 Feb; 19(1):50-7. PubMed ID: 19430406
[TBL] [Abstract][Full Text] [Related]
20. Whole body PET/CT in the follow-up of asymptomatic patients with stage IIB-IIIB cutaneous melanoma
Koskivuo I; Kemppainen J; Giordano S; Seppänen M; Veräjänkorva E; Vihinen P; Minn H
Acta Oncol; 2016 Nov; 55(11):1355-1359. PubMed ID: 27553064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
